Polyacetal-doxorubicin conjugates designed for pH-dependent degradation.

PubWeight™: 0.92‹?›

🔗 View Article (PMID 14624622)

Published in Bioconjug Chem on November 19, 2003

Authors

Ryan Tomlinson1, Jorge Heller, Steve Brocchini, Ruth Duncan

Author Affiliations

1: Biomedical Polymers Group, Department of Pharmaceutics, The School of Pharmacy, University of London, UK.

Articles by these authors

Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater (2004) 2.03

Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol (2005) 1.53

Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. J Control Release (2008) 1.46

Intracellular fate of bioresponsive poly(amidoamine)s in vitro and in vivo. J Control Release (2009) 1.43

Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol (2006) 1.34

PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem (2005) 1.27

Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol (2004) 1.26

Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem (2007) 1.16

Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J Control Release (2006) 1.15

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15

Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond) (2013) 1.11

Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev (2009) 1.08

Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed Engl (2005) 1.06

Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Adv Drug Deliv Rev (2003) 0.96

Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release (2006) 0.94

Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses. PLoS Comput Biol (2011) 0.93

Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin. Int J Pharm (2008) 0.93

Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev (2009) 0.91

Hybrid polymer therapeutics incorporating bioresponsive, coiled coil peptide linkers. Biomacromolecules (2010) 0.90

Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation B16F10 cells and use to study the intracellular fate of HPMA copolymer - doxorubicin. J Drug Target (2006) 0.89

Anomalous properties of spray dried solid dispersions. J Pharm Sci (2009) 0.89

Identification and insertion of 3-carbon bridges in protein disulfide bonds: a computational approach. Nat Protoc (2007) 0.88

Site-specific PEGylation at histidine tags. Bioconjug Chem (2012) 0.87

Structural studies of biologically active glycosylated polyamidoamine (PAMAM) dendrimers. J Mol Model (2010) 0.87

Characterization and stability of ternary solid dispersions with PVP and PHPMA. Int J Pharm (2011) 0.87

PEGylation and its impact on the design of new protein-based medicines. Future Med Chem (2014) 0.86

Comparative binding of disulfide-bridged PEG-Fabs. Bioconjug Chem (2012) 0.86

HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J Drug Target (2002) 0.85

The effect of dextrin-rhEGF on the healing of full-thickness, excisional wounds in the (db/db) diabetic mouse. J Control Release (2011) 0.85

From sequence to 3D structure of hyperbranched molecules: application to surface modified PAMAM dendrimers. J Mol Model (2011) 0.84

PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug Chem (2003) 0.84

LEAPT: lectin-directed enzyme-activated prodrug therapy. Proc Natl Acad Sci U S A (2004) 0.84

POE/PLGA composite microspheres: formation and in vitro behavior of double walled microspheres. J Control Release (2003) 0.84

Synthesis and endosomolytic properties of poly(amidoamine) block copolymers. Macromol Biosci (2004) 0.83

Double walled POE/PLGA microspheres: encapsulation of water-soluble and water-insoluble proteins and their release properties. J Control Release (2003) 0.83

Polyacetal and poly(ortho ester)-poly(ethylene glycol) graft copolymer thermogels: preparation, hydrolysis and FITC-BSA release studies. J Control Release (2006) 0.83

Poly(2-methacryloyloxyethyl phosphorylcholine) for protein conjugation. Bioconjug Chem (2008) 0.83

Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake. Biomacromolecules (2006) 0.82

Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules (2005) 0.81

A biomedical library of serinol-derived polyesters. J Control Release (2005) 0.81

Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker. Macromol Biosci (2009) 0.81

The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery. J Control Release (2008) 0.80

Fab-PEG-Fab as a potential antibody mimetic. Bioconjug Chem (2013) 0.80

Synthesis and preliminary evaluation of poly(amidoamine)-melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics. Int J Pharm (2005) 0.79

Dextrin-phospholipase A2: synthesis and evaluation as a bioresponsive anticancer conjugate. Biomacromolecules (2009) 0.79

Cell uptake and trafficking behavior of non-covalent, coiled-coil based polymer-drug conjugates. Macromol Rapid Commun (2010) 0.79

HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J Drug Target (2005) 0.79

HPMA copolymer-1,5-diazaanthraquinone conjugates as novel anticancer therapeutics. J Drug Target (2004) 0.78

Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. J Biomed Mater Res A (2003) 0.78

Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics II. Identification of endosomal and lysosomal compartments in HepG2 cells combining single-step subcellular fractionation with fluorescent imaging. J Drug Target (2007) 0.78

Polyacetal-diethylstilboestrol: a polymeric drug designed for pH-triggered activation. J Drug Target (2004) 0.77

Bioresponsive dextrin-rhEGF conjugates: in vitro evaluation in models relevant to its proposed use as a treatment for chronic wounds. Mol Pharm (2010) 0.77

Semisolid, self-catalyzed poly(ortho ester)s as controlled-release systems: protein release and protein stability issues. J Pharm Sci (2002) 0.77

A new reagent for stable thiol-specific conjugation. Bioconjug Chem (2014) 0.77

Polymer-protein and polymer-drug conjugates in cancer therapy. Curr Opin Investig Drugs (2003) 0.77

Total synthesis and preliminary biological evaluation of cis-solamin isomers. J Org Chem (2004) 0.76

Characterisation of ilomastat for prolonged ocular drug release. AAPS PharmSciTech (2012) 0.76

Dextrin-trypsin and ST-HPMA-trypsin conjugates: enzyme activity, autolysis and thermal stability. Int J Pharm (2009) 0.76

Polymer coiled-coil conjugates: potential for development as a new class of therapeutic "molecular switch". Biomacromolecules (2010) 0.76

Synthetic approaches to uniform polymers. Adv Drug Deliv Rev (2006) 0.76

Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates. Biomacromolecules (2007) 0.76

Studies on the mechanism of action of dextrin-phospholipase A2 and its suitability for use in combination therapy. Mol Pharm (2010) 0.75

The Influence of Scleral Flap Thickness, Shape, and Sutures on Intraocular Pressure (IOP) and Aqueous Humor Flow Direction in a Trabeculectomy Model. J Glaucoma (2016) 0.75

Preparation, characterization, and in vitro evaluation of physostigmine-loaded poly(ortho ester) and poly(ortho ester)/poly(D,L-lactide-co-glycolide) blend microspheres fabricated by spray drying. Biomaterials (2004) 0.75

Characterising the size and shape of polyamidoamines in solution as a function of pH using neutron scattering and pulsed-gradient spin-echo NMR. Int J Pharm (2006) 0.75

Impact of polymer tacticity on the physico-chemical behaviour of polymers proposed as therapeutics. Int J Pharm (2011) 0.75

Editorial. J Control Release (2004) 0.75

Solid-state protein formulations. Ther Deliv (2015) 0.75

Evaluation of Dimensional and Flow Properties of ExPress Glaucoma Drainage Devices. J Glaucoma (2016) 0.75

Diethylstilbestrol glutamate as a potential substrate for ADEPT. J Drug Target (2006) 0.75

Poly(amidoamine) salt form: effect on pH-dependent membrane activity and polymer conformation in solution. Biomacromolecules (2004) 0.75

Interaction of an endosomolytic polyamidoamine ISA23 with vesicles mimicking intracellular membranes: A SANS/EPR study. Macromol Biosci (2010) 0.75

Dendrimer-based drugs as macromolecular medicines. Biotechnol Genet Eng Rev (2006) 0.75

Effect of glass composition on the degradation properties and ion release characteristics of phosphate glass--polycaprolactone composites. Biomaterials (2005) 0.75

Approaches for quantifying and managing diffuse phosphorus exports at the farm/small catchment scale. J Environ Qual (2009) 0.75

Post surgical pain management with poly(ortho esters). Adv Drug Deliv Rev (2002) 0.75

Molecular dynamic simulations of ocular tablet dissolution. J Chem Inf Model (2013) 0.75

2. Commentary on dendrimers: why dendrimers?: Original research article: Relationship between structure and biocompatibility in vitro preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers (2000). J Control Release (2014) 0.75

Studies on the mechanism of interaction of a bioresponsive endosomolytic polyamidoamine with interfaces. 1. Micelles as model surfaces. Biomacromolecules (2007) 0.75